Reports linking the antibiotic Tygacil (tigecycline) to numerous deaths have prompted the watchdog group Public Citizen to petition the FDA to add a Black Box Warning to the drug’s label. The group is also calling on the administration to require a medication guide to be distributed to patients, as well as a ‘Dear Doctor’ letter to physicians warning them of the dangers associated with using the product. If you or someone you love has been injured by Tygacil, and you’re interested in filing a Tygacil class action lawsuit against the manufacturers, our lawyers can help.
Free Tygacil Class Action Lawsuit Evaluation: If you or a loved one has been injured by Tygacil, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of Tygacil and we can help.
What is Tygacil?
When it first hit the market in 2005, Tygacil was approved by the FDA to treat complicated skin and intra-abdominal infections. In 2009, Tygacil’s approval was extended to include the treatment of community-acquired pneumonia.
Tygacil is similar to tetracycline antibiotics, which work against large numbers of bacteria. The medicine bonds to bacterial ribosomes, which are organelles inside the bacteria that manufacture the cell’s proteins. This prevents the ribosomes from making important proteins needed for growth and multiplication of the bacteria. Tygacil does not kill bacteria – it simply prevents it from replicating.
Tygacil Side Effects
The most serious side effect reported in Tygacil users is unexpected death. More moderate health complications caused by the drug may include:
- diarrhea that is watery or bloody
- severe headache
- pain behind your eyes
- ringing or throbbing in your ears
- problems with vision
- severe pain in your upper stomach spreading to your back
- fast heart rate
- feeling like you might pass out
- easy bruising or bleeding
- unusual weakness
- sleep problems (insomnia)
- increased sweating
- vaginal yeast infection
FDA Warning on Tygacil
In 2010, the FDA issued a press release announcing that the intravenous (IV) use of Tygacil had been linked to an increased risk of mortality compared to of other antibiotic medications. FDA stated that alternatives to Tygacil should be prescribed to patients with serious infections. The administration also required Pfizer to update Tygacil’s label to include information about the increased risk of mortality. However, according to Public Citizen’s petition, these warnings are inadequate because they fail to describe appropriate restrictions for the use of the product.
“Given the approximately 30 percent higher rate of mortality in subjects receiving tigecycline, as well the significantly higher rates of failures to cure serious infections, in comparison to subjects treated with comparator antibiotics, the content and placement of the warnings in the current drug label are woefully insufficient,” said Dr. Michael Carome, deputy director of Public Citizen’s Health Research Group. “Because of the increased death rate and the likely inappropriate use of tigecycline as a first-line, rather than last-resort, antibiotic for serious infections without simultaneous administration of other antibiotics, it is inexcusable that there is currently no black box warning for tigecycline. Such a warning, accompanied by stronger warnings describing appropriate restrictions on its use in other parts of the label, clearly is warranted to more effectively advise physicians about the dangers of using tigecycline to treat serious infections and to better protect public health.”
About Tygacil Class Action Lawsuits
Although we are a nationally recognized class action firm, the Products Liability Litigation Group at our law firm has decided against the filing of a Tygacil Class Action Lawsuit, and is currently filing individual claims on behalf of injured individuals and/or their family members who have been injured by Tygacil.
A class action is a type of lawsuit filed with the court on behalf of large group of people or “class” of individuals that have been injured or wronged. The class is represented by the law firm and the case is generally decided upon a single member of the class who is sometimes referred to as the “class representative or class rep.”
Why Our Law Firm Is Filing Individual Lawsuits Opposed To a Class Action
In some instances, a class action may offer some advantages, as they aggregate a large number of individualized claims into one representational lawsuit. The aggregation can increase the efficiency of the legal process, lower the costs of litigation and in some cases offer the solution to a common problem wherein small recoveries do not provide the incentive for any individual or law firm to file an individual lawsuit.
However, a class action suit can also be a detriment to many class members, as they are often forced into a blanket “low ball settlement” and higher attorney fees. At Schmidt & Clark, LLP we understand that our clients are suffering emotionally and economically due to loss of wages and/or high medical bills and we plan to maximize each client’s recovery by filing individual Tygacil lawsuits on their behalf.
Do I Have a Tygacil Class Action Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Tygacil lawsuits. We are handling individual litigation nationwide and currently accepting new Tygacil injury and death cases in all 50 states.
Free Tygacil Class Action Lawsuit Evaluation: If you or a loved one has been injured by Tygacil, you should contact our law firm immediately. You may be entitled to compensation by filing a Tygacil suit and we can help.